Utilizamos cookies para poder estudiar y mejorar la experiencia de usuario de los visitantes de la web. Si continuas navegando por la web entendemos que aceptas nuestra política de cookies.

Listado de ganadores de la beca internacional Josep Carreras - E.D Thomas

  • 1991-1992-1993: Dr. Catherine Verfaillie, University of Minnesota (Estados Unidos). CML: purification of bening stem cells useful for autologous transplant and generation of autologous A-LAK suitable for post-transplant consolidation.
  • 1992-1993-1994: Dr. Alessandra Cesano, The Winstar Institute (Estados Unidos). An in-vivo model of cell-mediated lyisi against acute lymphoblastic leukemia.
  • 1993-1994-1995: Dr. Ana Carrera, Fundación Severo Ochoa / Centro de Biología Molecular / Universidad Autonoma de Madrid (España). Study of the effects of pp56lck mutants with substrate specificity on cell transformation.
  • 1993-1994-1995: Dr. Robert S. Negrin, Standford University Hospital (Estados Unidos). Biology of cytokine induced natural killer cells.
  • 1994-1995-1996: Dr. Bruce C. Clurman, Fred Hutchinson Cancer Research Center (Estados Unidos). Targeted disruption of Aessential genes in lymphoma cells.
  • 1995-1996-1997: Dr. I. Sanchez-García, Instituto de Microbiología Bioquimica CSIC / Universidad de Salamanca (España). Gene therapy for the treatment of Philadelphia cromosome-positive leukaemia.
  • 1996-1997-1998: Dr. Martin Stattler, Dana Farber Cancer Institute - Boston (Estados Unidos). Role of Activationof Stat Proteins by BCR/ABL in the pathogenesis of chronic myeloid leukemia (CML).
  • 1997-1998-1999: Dr. Ralf Huss, Institute of Pathology, University of Munich (Alemania). Mechanisms of differentiation, proliferation and cell clycle progression in hematopoietic stem cells: a model for leukemic transformation.
  • 1997-1998-1999: Dr. Mathew Fero, Fred Hutchinson Cancer Research Center (Estados Unidos). Tumor suppression by CDK Inhibitors.
  • 1998-1999-2000: Dr. Koichi Akashi, Stanford University School of Medicine (Estados Unidos). Identification of Human Common Lymphoid Progenitor.
  • 1999-2000-2001: Dr. Francesco Galimi, The Salk Institute, La Jolla, California (Estados Unidos). Role of Telomere Maintenance in Human Hematopoietic Stem Cells: A Gene Transfer Approach.
  • 2000-2001-2002: Dr. Claudia Huettner, Beth Israel Deaconess Medical Center - Harvard Institutes of Medicine (Estados Unidos). Conditional transgenic models of BCR/ABL leukemia.
  • 2000-2001-2002: Dr. Soheil Meshinchi, Fred Hutchinson Cancer Research Center Seattle (Estados Unidos). Biologic and clinical significance of Flt3 internal tandem duplication in pediatric Acute Myeloid Leukemia.
  • 2000-2001-2002: Dr. Elena Tassi, Instituto Nazionale Tumori Milano (Italia). Molecular Mechanism involved in the resistance to BCR/ABL inhibition in neoplastic cells (renució a la beca que fue concedida posteriormente a la Dra. Gumby).
  • 2000-2001-2002: Dra. Rosalyn Gumby, Instituto Nazionale Tumori Milano (Italia). Investigation of the Mechanisms of resistance to the BCR/ABL inhibitor STI571.
  • 2001-2002-2003: Dr. Homayoun Vaziri, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts (Estados Unidos). Molecular determinants of cellular senescense and immortalization.
  • 2002-2003-2004: Dr. Emmanuelle Pessegue, Stanford University (Estados Unidos). Towards a better understanding of molecular mechanisms of myeloid leukemia.
  • 2003-2004-2005: Dr. Alejandro Barbieri, Washington University School of Medicine (Estados Unidos). Role of Ras interference 1 (rin) in acute and chronic myelogenous leukaemias.
  • 2004-2005-2006: Dr. Yukiko Yamashita, Stanford University (Estados Unidos). The mechanisms that control stem cell fate between proliferation and differentiation by asymmetric stem cell division.
  • 2005-2006-2007: Dr. Golam Mohi, Beth Israel Deaconess Medical Center - Harvard Medical School - Boston (Estados Unidos). The Gab2/Shp2 Pathway in Human leukaemia.
  • 2006-2007-2008: Dr. Pablo Menéndez, Institute of Cancer Research- Chester Beatty Laboratories - London (Inglaterra). Developmental Impact of MLL-AF4 Leukaemic Fusion Gene on Human Stem Cell Fate.
  • 2007-2008-2009: Dr. Karl Novina, Dana Farber Cancer Institute, Boston (Estados Unidos). Mouse modeling of Micro-RNA function in chronic lymphocytic leukemia.
  • 2008-2009-2010: Dr. Jean François Rual, Harvard Medical School - Dept. of Cell Biology, Boston (Estados Unidos). Molecular and Genetic definition of the Notch signalling network, a major factor in T-ALL.
  • 2009-2010-2011: Dr. Hanna Cullup, Mater Medical Research Institute South Brisbane (Australia). Antibody-mediated dendritic cell depletion to attenuate GVHD and promote GVL.
  • 2010-2011-2012: Dr. Adlen Foudi, Harvard Medical School, Stem Cell Institute, Boston (Estados Unidos). Role of Gfi-1 family of transcriptional repressors in normal hematopoiesis and leukaemia.
  • 2011-2012-2013: Dr. Robert S. Welner, Ph.D. Beth Israel Deaconess, Boston (Estados Unidos). β-catenin maintains leukemic stem cells by suppressing transcription factors required for differentiation.
  • 2012-2013-2014: Dr. Pedro Pablo Medina, Kline Biology Laboratory, Yale University (Estados Unidos). Micro-RNA-21 induced haematological malignancies.
  • 2013-2014-2015: Dr. Thomas Schmitt, Fred Hutchinson Cancer Research Center, Seattle (Estados Unidos). Targeting Leukemia with Enhanced-Affinity TCR Gene Therapy.
Página web actualizada 09/11/2017 16:42:57